Symbol
| CD2AP
| contributors: shn/mct - updated : 13-09-2016
|
HGNC name
| CD2-associated protein
|
HGNC id
| 14258
|
corresponding disease(s)
|
FSGS3
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
constitutional
|  
|  
| --over
|  
|
in Congenital nephrotic syndrome of the Finnish type (CNF)  | constitutional
|  
|  
| --low
|  
|
in diabetic conditions in podocytes via PI3-K/Akt signaling  | |
Susceptibility
|
to glomerulosclerosis and glomerular disease to Alzheimer disease toend-stage renal disease (ESRD) in patients with type 1 diabetes |
Variant & Polymorphism
SNP
| strongly associated with Alzheimer disease  |
|
CD2AP gene variants may contribute to susceptibility to ESRD in patients with type 1 diabetes |
|
|
Candidate gene
Marker
Therapy target
| | | |
| CD2AP-deficient mice die at 6 to 7 weeks of age from renal failure. Knockout mice exhibited exhibited nephrotic syndrome and renal failure: defects in epithelial cell foot processes, mesangial cell hyperplasia and extracellular matrix deposition  | |
Mice lacking CD2AP exhibit a congenital nephrotic syndrome characterized by extensive foot process effacement  |
|
Mice lacking CD2AP die at 6 weeks of age. Mice with CD2AP haploinsufficiency developed glomerular changes at 9 months and had increased susceptibility to glomerular injury by nephrotoxic antibodies or immune complexes  |